<DOC>
	<DOCNO>NCT00755274</DOCNO>
	<brief_summary>Primary Objective : To provide Center Biologics Evaluation Research ( CBER ) serum collect healthy child receive 2008-2009 formulation inactivate , split-virion influenza vaccine Fluzone® study . Observational Objectives : To describe safety 2008-2009 pediatric formulation Fluzone® vaccine , administer one- two-dose schedule accordance Advisory Committee Immunization Practices ( ACIP ) recommendation , child ≥ 6 month &lt; 5 year age . To describe immunogenicity 2008-2009 pediatric formulation Fluzone® vaccine , administer one- two-dose schedule accordance ACIP recommendation , child ≥ 6 month &lt; 5 year age .</brief_summary>
	<brief_title>Annual Study Serum Collection Immunogenicity Safety Evaluation Healthy Children Receiving Fluzone®</brief_title>
	<detailed_description>The Advisory Committee Immunization Practices ( ACIP ) recent year recommend healthy child age 6 59 month receive influenza vaccine . Because grow emphasis influenza immunization infant young child , Center Biologics Evaluation Research ( CBER ) express interest receiving serum child vaccinate current formulation Fluzone® vaccine . These serum test evaluate individual 's immune response current formulation Fluzone® vaccine also use evaluate circulating influenza strain order support formulation recommendation subsequent year ( particularly influenza B strain , predominantly affect young ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant ≥ 6 month &lt; 5 year age . Participant consider good health basis report medical history limit historydirected physical examination . Parent/legal acceptable representative willing able bring subject schedule visit comply study procedure entire duration study . Parent/legal acceptable representative willing able provide inform consent . Subject born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg ( 5.5 lb ) . Reported allergy egg protein , chicken protein , constituent vaccine . History severe adverse event influenza vaccine . Laboratoryconfirmed influenza infection vaccination influenza 6 month precede enrollment study . Any vaccination schedule Visit 1 Visit 2 . Planned participation interventional clinical trial participation study . Known suspect impairment immunologic function receipt immunosuppressive therapy immunoglobulin since birth . Personal immediate family history congenital immune deficiency . Developmental delay , neurologic disorder , seizure disorder . Chronic medical , congenital , developmental disorder . Known Human immunodeficiency virus ( HIV ) positive mother . Prior personal history GuillainBarré syndrome . Any condition , opinion Investigator , would pose health risk subject interfere evaluation vaccine . Thrombocytopenia bleed disorder contraindicate intramuscular ( IM ) vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>Orthomyxoviridae Infections</keyword>
	<keyword>Influenza vaccine</keyword>
</DOC>